ALDA Pharmaceuticals Corp.

ALDA Pharmaceuticals Corp.

April 03, 2007 09:30 ET

ALDA Develops Safe Gel to Prevent Sexually Transmitted Infections

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - April 3, 2007) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") has completed the development of its T36® Microbicide Gel which is designed to prevent the spread of HIV and other Sexually Transmitted Infections ("STI's"). STI prevention is important because nearly 40 million people are now infected with HIV and 4 to 5 Million new HIV infections have been reported every year since 1999. The number of all new STI's, including HIV, is greater than 300 million per year.

The importance of STI prevention is further illustrated by the recent announcement from the Government of Canada and the Bill & Melinda Gates Foundation that $138 million will be invested in the development of vaccines against HIV, a process which could take 10 years or longer. Even if vaccine development is successful, preventative measures will always be required. ALDA is now pursuing a plan to provide T36® Microbicide Gel to those most in need on a humanitarian basis so that the necessary clinical data can be obtained for full product registration.

About ALDA

ALDA's patent-pending T36® Microbicide Gel contains infection-control ingredients in very low concentrations that disrupt the physical structure of microbes rather than interfering with their metabolic pathways. The competitive advantage is the ability to kill STI-causing organisms while preventing microbial resistance, side effects or toxicity.

Terrance G. Owen, Ph.D., MBA, President, CEO and Director

ALDA Pharmaceuticals Corp.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information